NCT00531336View on ClinicalTrials.gov

MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Macular Degeneration
Interventions
DRUG

intravitreal injection of Bevacizumab (Avastin)

1.25 mg Avastin intravitreally applied once in arm 1 every 6 weeks in arm 2

DRUG

Pegaptanib (Macugen)

0.3 mg intravitreally applied every 6 weeks as long as required

Trial Locations (1)

A1030

Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery, Vienna

All Listed Sponsors
lead

The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

OTHER

NCT00531336 - MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen | Biotech Hunter | Biotech Hunter